SynthesisClinical endocrinology2026
Metabolic Effects of Modified-Release Hydrocortisone Versus Short Acting Conventional Oral Glucocorticoids in Adrenal Insufficiency: A Systematic Review and Meta-Analysis.
Synthesis in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAdrenal insufficiency's (AI) lifelong replacement therapy by conventional glucocorticoid (GC) regimens poorly mimics physiological cortisol, leading to poor adherence and metabolic abnormalities. Modified-release hydrocortisone (MR-HC) provides a more physiological cortisol replacement with potentially enhanced outcomes. This study assessed comparative evidence of MR-HC versus GC in patients with AI.
designSystematic review and meta-analysis.
methodsComparative articles published until July 2025 were searched in PubMed, Scopus and Web of Science. Glucose metabolism, anthropometrics, lipid profile and blood pressure were the primary outcomes; bone health parameters and safety and tolerability measures were secondary outcomes.
resultsAcross six included studies (n = 400), MR-HC was associated with significant reductions in BMI (mean difference -1.1, 95% CI -2.11 to -0.1) and waist circumference (-5.03, 95% CI-8.54 to -1.51), without significant changes in body weight. MR-HC lowered total cholesterol (-10.64, 95% CI -19.86 to -1.42), systolic blood pressure (-6.03, 95% CI -10.95 to -1.1) and diastolic blood pressure (-4.35, 95% CI -7.37 to -1.34). Glucose metabolic outcomes (fasting glucose and HbA1c) did not differ significantly between the groups, but sensitivity analysis suggested a potential HbA1c benefit with MR-HC. Bone health results favoured MR-HC for lumbar spine T-score (0.69, 95% CI 0.16 to 1.22), and femoral neck T-score (0.64, 95% CI 0.16 to 1.12). Safety measures favoured MR-HC for Infection score (-1.7, 95% CI -2.6 to -0.8), and flu-like events (-1.0, 95% CI -1.6 to -0.4), but not vertebral fractures (0.20, 95% CI 0.03 to 1.55), or AddiQol score (4.00, 95% CI -0.68 to 8.68).
conclusionsMR-HC demonstrated improved effects on anthropometric measures, lipid profile, blood pressure, bone mineral density, and safety and tolerability compared to conventional GC with no apparent differences in glucose metabolism. These findings validate MR-HC as a better regimen, but await larger long-term trials for confirmation.
trial registrationThis study was prospectively registered on PROSPERO (CRD420251074980). Available at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251074980.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.